Compare · FSTX vs LLY
FSTX vs LLY
Side-by-side comparison of F-star Therapeutics Inc. (FSTX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FSTX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.27T.
- LLY has hit the wire 33 times in the past 4 weeks while FSTX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 4 for FSTX).
- Company
- F-star Therapeutics Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.27T
- 1M return
- -
- +15.83%
- 1Y return
- -
- +46.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 33
- Recent ratings
- 4
- 25
F-star Therapeutics Inc.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest FSTX
- Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
- Levicept Appoints Eliot Forster as CEO
- SEC Form 15-12G filed by F-star Therapeutics Inc.
- SEC Form SC 13G filed by F-star Therapeutics Inc.
- SEC Form EFFECT filed by F-star Therapeutics Inc.
- SEC Form EFFECT filed by F-star Therapeutics Inc.
- SEC Form EFFECT filed by F-star Therapeutics Inc.
- SEC Form EFFECT filed by F-star Therapeutics Inc.
- SEC Form EFFECT filed by F-star Therapeutics Inc.
- SEC Form 4: Kayitalire Louis returned $178,135 worth of shares to the company (25,019 units at $7.12), closing all direct ownership in the company to satisfy tax liability
Latest LLY
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
- President, Chair, and CEO Ricks David A gifted 23,538 shares (SEC Form 4)
- Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $7,012,600 worth of shares (5,000 units at $1,402.52) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & CFO Montarce Lucas converted options into 1,610 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 6% to 17,191 units (SEC Form 4)
- EVP & Pres., Mfg. Operations Hernandez Edgardo converted options into 2,530 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 3% to 47,490 units (SEC Form 4)
- EVP, Chief People Officer Dozier Eric converted options into 2,300 shares and covered exercise/tax liability with 1,019 shares, increasing direct ownership by 9% to 15,520 units (SEC Form 4)
- EVP & President, Card Met Hlth Custer Kenneth L. converted options into 3,220 shares and covered exercise/tax liability with 1,425 shares, increasing direct ownership by 18% to 11,935 units (SEC Form 4)